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Background: Janus kinases (JAK1–3, TYK2) mediate cytokine signals in the regulation of 2 
hematopoiesis and immunity. JAK2 clinical mutations cause myeloproliferative neoplasms 3 
and leukemia and the mutations strongly concentrate in the regulatory pseudokinase 4 
domain, JAK homology 2, JH2. Current clinical JAK inhibitors target the tyrosine kinase 5 
domain and lack mutation- and pathway-selectivity.  6 
Objective: To characterize mechanisms and differences for pathogenic and cytokine-7 
induced JAK2 activation to enable design of novel selective JAK inhibitors. 8 
Methods: Systematic analysis of JAK2 activation requirements using structure-guided 9 
mutagenesis, cell signaling assays, microscopy, and biochemical analysis. 10 
Results: Distinct structural requirements identified for activation of different pathogenic 11 
mutations. Specifically, the predominant JAK2 mutation V617F is the most sensitive to 12 
structural perturbations in multiple JH2 elements (C helix (αC), SH2-JH2 linker and ATP-13 
binding site). In contrast, activation of K539L is resistant to most perturbations. Normal 14 
cytokine signaling shows distinct differences in activation requirements: JH2 ATP-binding 15 
site mutations have only a minor effect on signaling, while JH2 αC mutations reduce 16 
homomeric (JAK2-JAK2) EPO signaling, and almost completely abrogate heteromeric 17 
(JAK2-JAK1) IFNγ signaling, potentially by disrupting a dimerization interface on JH2. 18 
Conclusions: These results suggest that therapeutic approaches targeting the JH2 ATP-19 
binding site and αC could be effective in inhibiting most pathogenic mutations. JH2 ATP-20 
site targeting have potential for reduced side-effects by retaining EPO and IFNγ functions. 21 
Simultaneously, however, we identify the JH2 αC interface as a potential target for 22 
pathway-selective JAK inhibitors in diseases with unmutated JAK2, thus providing new 23 
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Janus kinases (JAKs) are non-receptor tyrosine kinases critically involved in cellular 34 
signaling, regulating the immune system, development, differentiation, and growth 1. 35 
Signaling through JAKs are numerous proinflammatory cytokines, including interleukins 36 
(IL-)2, IL-3, IL-4, IL-6, IL-9, IL-12, IL-13, IL-15, IL-23, and granulocyte-macrophage colony 37 
stimulating factor (GM-CSF), making JAK inhibition a tempting drug target for the 38 
treatment of inflammatory diseases 2. Similarly, aberrant signaling caused by activating 39 
gain-of-function (GOF) mutations in JAKs underlie multiple neoplastic diseases, including 40 
myeloproliferative neoplasms 3. Indeed, the recent advent of JAK inhibitors for the 41 
treatment of both of these disease groups has made understanding the mechanisms of 42 
JAK-STAT signaling highly relevant to the clinical immunologist 4. 43 
JAKs associate with type I and type II cytokine receptors and mediate cytokine signals 44 
from activated receptors to signal transducers and activators of transcription (STATs), 45 
which upon phosphorylation by JAKs, move to the nucleus to activate transcription. The 46 
four JAKs in mammals (JAKs 1–3, TYK2) signal at homodimeric (JAK2) or heterodimeric/-47 
oligomeric (all JAKs) receptors and consist of four domains (N-to-C): a 4.1-band, ezrin, 48 
radexin, moiesin (FERM) domain, a Src homology 2 (SH2)-like domain, a pseudokinase 49 
domain (JAK homology 2, JH2), and a protein tyrosine kinase domain (JH1). FERM-SH2 50 
mediate association to cytokine receptors 5. JH2 serves a dual role; it inhibits the tyrosine 51 
kinase activity of JH1 in the basal state, and is required for full activation upon cytokine 52 
stimulation 6-9. 53 
JH2 is a mutational hotspot for clinical JAK mutations. The somatic JAK2 V617F mutation 54 
in exon 14, for example, causes ligand-independent JAK2 activation and underlies >95% 55 
of polycythemia vera and >50% of essential thrombocythemia and primary myelofibrosis 56 

















including K539L), exon 16 (including R683S/G), and some in JH1 3. JH2 GOF mutations in 58 
other JAKs cause leukemias and loss-of-function mutations cause immune deficiencies 3, 59 
highlighting the dual regulatory role of JH2 6,7,11. Recent structural information of the JH2-60 
JH1 interaction explains the inhibitory function of JH2 9,12. In this interaction, the C helix 61 
(αC) side of JH2 binds to JH1 in a front-to-back orientation (Figure 1 A) leading to 62 
conformational restriction of JH1 and inhibition of kinase activity 12.  63 
While multiple GOF mutations lie in the JH2-JH1 interface, disruption of the JH2-JH1 64 
interaction alone does not fully explain the high activation potential of all GOF mutations––65 
including JAK2 V617F or JAK2 K539L. We speculate that these mutations utilize the 66 
known, but molecularly incompletely characterized, stimulatory function of JH2 to activate 67 
JAK2.  68 
Current clinical JAK inhibitors used to treat diseases caused by JAK2 GOF mutations 69 
target JH1 and thus do not distinguish between mutated and wild-type (WT) JAK2 and are 70 
unable to eradicate the disease. Furthermore, they frequently lead to anemia caused by 71 
suppression of normal erythropoietin (EPO) signaling due to inhibition of JAK2 WT 72 
functions 13. In contrast, in inflammatory diseases, in which usually no JAK mutations are 73 
present (with rare exceptions, see e.g., ref 14) current inhibitors are effective in 74 
approximately half of the patients, but also affect unwanted cytokine functions and show 75 
side-effects such as reactivation of viral infections and anemia 4. Thus, there is a clinical 76 
need for more effective and selective JAK inhibitors able to discriminate between 77 
pathogenic and cytokine-induced signaling and/or discriminate between different types of 78 
JAK-mediated signaling pathways. 79 
However, a potential paradigm shift in JAK inhibition is emerging, as molecular 80 

















target for novel modulators of JAK activity 15.  JH2 harbors the majority of human 82 
pathogenic JAK mutations, and we recently identified the JAK JH2 ATP-binding site as a 83 
potential drug target by demonstrating that activation by the pathogenic JAK2 JH2 GOF 84 
mutations K539L, V617F, and R683S is reliant on the stabilizing effect of ATP binding on 85 
JH2 16. Furthermore an ATP-competitive compound targeting TYK2 JH2 has been 86 
demonstrated to efficiently and specifically inhibit cytokine signaling 17. 87 
Here, we provide a systematic analysis of the molecular basis for different JH2-targeting 88 
intervention strategies. We identify distinct differences in activation mechanisms between 89 
clinical JAK2 GOF mutations in terms of reliance on specific activating JH2 molecular 90 
interfaces and JAK2-mediated receptor dimerization.  Analysis of cytokine-induced 91 
signaling shows differences in JH2 interface requirements between homodimeric (EPO) 92 
and heterodimeric (Interferon γ, IFNγ) JAK2 activation. These results provide novel 93 
insights into pathogenic and cytokine induced JAK2 activation mechanisms that have 94 

















Materials and Methods 96 
See Supplementary material for full details of Materials and Methods. Briefly, for 97 
immunoblotting and luciferase reporter assays, JAK2-deficient γ2A human fibrosarcoma 98 
cells 18 were transfected with the designated combination of human JAK2-HA, human HA-99 
EPOR (both in pCIneo), and human STAT5-HA (in pXM) using FuGENE HD (Promega) for 100 
24–48 h. For reporter assays, a Firefly luciferase reporter plasmids for STAT5 (Spi-Luc 1) 101 
or STAT1 (IRF-GAS 19) were added along with a constitutively expressing Renilla 102 
luciferase plasmid. Cytokine stimulation was done in starvation medium without FBS for 30 103 
min (for immunoblotting) or 5 h (for reporter assays) unless otherwise specified, with 104 
recombinant human EPO (Roche), or IFNγ (Peprotech). For immunoblotting, cells were 105 
washed with PBS, lysed in Triton X-100 lysis buffer, and complete lysates run on lab-made 106 
SDS-PAGE gels. Immunoblots were blocked with bovine serum albumin and incubated 107 
with primary antibodies: HA Tag (Aviva Systems Biology), phospho-JAK2 (Millipore), 108 
phospho-STAT5 (Cell Signaling), phospho-STAT1 (Cell Signaling), STAT1 (BD 109 
Biosciences), or actin (Millipore), and a mixture of goat-anti-rabbit and goat-anti-mouse 110 
DyLight secondary antibodies (both Thermo Fisher Scientific). Blots were read using an 111 
Odyssey CLx (LI-COR), and immunoblot signals quantified using Image Studio software 112 
(LI-COR) by manually assigning bands (See Supplementary Material and Figure S1). 113 
Reporter assays were detected using the DualGlo reporter assay kit (Promega) according 114 
to manufacturer’s instructions and normalized to readings from wells of unstimulated cells 115 
transfected with JAK2-HA WT. 116 
For qPCR analysis, γ2A cells were transfected for 28 h, starved for 16 h, stimulated for 2 h 117 
with 10 U/ml EPO or 10 ng/ml IFNγ, and RNA extracted using TRI Reagent (Molecular 118 
Research Center) according to manufacturer’s instructions. IRF1 gene expression was 119 

















GCATGAGACCCTGGCTAGAG-3’ and 5’-CTCCGGAACAAACAGGCATC-3’) and 121 
normalized to the expression of TATA-box binding protein (TBP). 122 
For in vitro kinase assays, recombinant JAK2 JH2-JH1 (residues 513–1132-6xHis) WT, 123 
I559F, and E592R proteins were expressed in High Five insect cells (Thermo Fisher 124 
Scientific) using the Bac-to-Bac expression system (Invitrogen) according to 125 
manufacturer’s instructions. Cells were lysed by freeze-thawing, clarified by centrifugation, 126 
and recombinant proteins purified using Ni-NTA agarose (Qiagen) followed by size-127 
exclusion chromatography in a HiLoad 16/600 Superdex 75 pg column (GE Healthcare). 128 
Protein concentrations were measured by Bradford assay (Bio-Rad) and enzymatic activity 129 
determined with Lance Ultra kinase assay (PerkinElmer) under conditions recommended 130 
by the manufacturer. Kinase reactions were performed in triplicate and results shown are 131 
representative from 2–3 individual experiments. 132 
For microscopy, cells were seeded on 35 mm glass bottom dish (MatTek), transfected with 133 
JAK2-YFP fusion constructs (in pEGFP) or EPOR-YFP/EPOR-CFP (in pBOF 20) overnight 134 
and starved for 8 h. Cells were fixed with 4% paraformaldehyde and 0.1% glutaraldehyde 135 
for 15 minutes at room temperature, washed, and kept in PBS at 4 °C before imaging on a 136 
Zeiss LSM 780 laser scanning confocal microscope using a Plan Apochromat 63x/1.4 oil 137 
immersion objective. FRET was monitored by acceptor photobleaching 21 and FRET 138 


















Suppressing mutations reveal differences in activation mechanisms of GOF 141 
mutations 142 
Studies on JAK2 activation mechanisms have identified several mutations capable of 143 
suppressing activation by pathogenic JAK2 GOF mutations (see Table 1, Figure 1, Figure 144 
2). These mutations, termed here ‘suppressing mutations’, localize in JH2 αC (F595A), in 145 
the C-terminus of the SH2-JH2 linker (F537A) and in the JH2 ATP-binding site (see Table 146 
1). Recently Leroy et al. identified an additional residue in the outer face of JH2 αC (JAK2 147 
E596) as an important link in the activation mechanism of V617F, but not of K539L, 148 
R683G, or of T875N 22. Notably, these suppressing mutations are functionally distinct from 149 
mutations that completely destabilize JH2 structure (e.g. JAK2 F739R refs 16,23 or deletion 150 
of JH2 αG 8), which mimic JH2 deletion resulting in increased basal activation and 151 
irresponsiveness to cytokines. 152 
The activation mechanisms and requirements of regulatory interfaces for different GOF 153 
mutations and cytokine-induced JAK2 activation have not been systemically analyzed. We 154 
thus set out to compare ligand-independent (pathogenic) and normal ligand-dependent 155 
JAK2 activation using suppressing mutations in JAK2-deficient γ2A fibroblast cells. We 156 
focused on the three previously identified regulatory regions in JH2: the ATP-binding site 157 
(JAK2 mutations I559F, G552A+G554A, or K677E) 16, the outer face of JH2 including αC 158 
(F595A, E596R) 12,22-25, and the C-terminus of the SH2-JH2 linker (F537A) 26. Additionally, 159 
we tested a novel JH2 αC outer face mutation, E592R, in order to analyze the involvement 160 
of the N-terminus of the JH2 αC. We further hypothesized that JH2 functions as a 161 
structural linker between FERM-SH2 and JH1 and, when structurally sound, is able to 162 
position JH1 for trans-autophosphorylation. To test this, we aimed to break up the putative 163 

















between the SH2-JH2 linker and the FERM F1-F2 loop (Figure 1). We also included JH1 165 
αC outer face mutations (E896A+E900A) analogous to the JH2 mutations E592R/E596R 166 
to test the function of JH1 αC as a potential interaction interface. 167 
We analyzed activation by three different pathogenic GOF JAK2 mutations predicted to 168 
have differing activation mechanisms (Figure 2): V617F (exon 14), which has been 169 
suggested to alter the conformation of the SH2-JH2 linker and thus indirectly affect the 170 
inhibitory JH2-JH1 interaction 12,26; R683S (exon 16), which is predicted to activate 171 
primarily by breaking the inhibitory JH2-JH1 interaction 9,12; and K539L (exon 12), which 172 
lies at the N terminus of JH2, and thus might also affect the SH2-JH2 linker, but whose 173 
activation mechanism has not been studied in detail. 174 
In accordance with previous reports 16,22,24,25 we found that ligand-independent JAK2 JH1 175 
activation loop (Y1007-Y1008, pJAK2) hyperphosphorylation caused by V617F is 176 
suppressed by JH2 ATP pocket and αC mutations (Figure 2 A and B, first panel). V617F-177 
induced pJAK2 is also suppressed by V511R, suggesting that the activation mechanism of 178 
V617F requires correct linking of JH2 to SH2. However, JAK2V617F activation is not 179 
sensitive to perturbation of JH1 αC (Figure 2 A and B, first panel). Downstream pSTAT1 180 
analysis correlated with pJAK2 levels. Effects of suppressing mutations on STAT5 181 
activation were analyzed in reporter assays with EPOR-HA coexpression (Figure 2 D), 182 
where the inhibition profile correlated with pJAK2 and pSTAT1 analysis with strongest 183 
inhibition with αC mutations and F537A. 184 
Activation by R683S was sensitive to all suppressing mutations in pJAK2 and pSTAT1 185 
analysis as well as in STAT5 transcriptional activation, and the ATP-binding site mutants 186 
showed slightly more suppression than mutations in αC. Interestingly, K539L was clearly 187 

















K539L in pJAK2, pSTAT1, and STAT5 activation. JH2 ATP-binding site mutations affected 189 
mainly JAK2 phosphorylation. These data suggest a distinct activation mechanism for 190 
K539L over V617F and R683S. 191 
Taken together, these results indicate that interactions involving JH2 are critical for 192 
hyperactivation of all JAK2 GOF mutants, but that the specific JH2-mediated interactions 193 
differ between the GOF mutations. 194 
The effect of suppressing mutations on cytokine activation 195 
Cytokine stimulation titrations with JAK2-HA V617F+suppressor double-mutant constructs 196 
showed that even strong suppression of basal V617F-induced activity did not inhibit 197 
cytokine-induced STAT5 transcriptional activation for EPO or STAT1 activation for IFNγ 198 
(Figure 3 A and B, respectively). Rather, the most potent suppressor mutations (F537A 199 
and all αC mutations) restored EPO sensitivity to be indistinguishable from JAK2 WT 200 
(Figure 3 A). For IFNγ, cytokine sensitivity was also restored, which was further 201 
corroborated with qPCR of induction of expression of the IFNγ-responsive gene Interferon 202 
regulatory factor 1 (IRF1). Interestingly, however, IFNγ-induced STAT1 activation with αC 203 
and F537A  mutations with V617F were lower than with JAK2 WT (Figure 3 B and C) 204 
suggesting potential specific involvement of these regions in IFNγ signaling. 205 
Previous work has suggested that suppressing mutations do not inhibit cytokine-induced 206 
signaling in a JAK2 WT background 16,22,24, but detailed analysis of sensitivity to different 207 
modes of JAK2-mediated signaling (homo- vs. heterodimeric) has been lacking. We thus 208 
analyzed cytokine-induced JAK2 activation using the mutation panel in a JAK2 WT 209 
background. Immunoblot analysis of JAK2-mediated STAT5 phosphorylation on 210 
homodimeric EPO receptor showed that, despite lower basal signaling activity, EPO-211 

















binding site mutations were virtually identical to JAK2 WT in their response to EPO. F595A 213 
and E592R in αC and F537A, however, showed diminished EPO-induced STAT5 214 
phosphorylation (Figure 4 A). Reporter assays showed similar results, albeit with 215 
differences even more pronounced (Figure 4 C). 216 
Strikingly, the same JH2 αC and SH2-JH2 linker mutations practically abolished 217 
heteromeric JAK2-JAK1-mediated STAT1 phosphorylation upon IFNγ stimulation (Figure 4 218 
B), while JH2 ATP-site mutations were again indistinguishable from JAK2 WT. In 219 
accordance with pSTAT1-immunoblot data, IFNγ-induced STAT1 transcription activity was 220 
almost completely abrogated for all αC mutations (including E596R) and F537A, whereas 221 
JH2 ATP-site mutations and V511R showed no significant decrease (Figure 4 D). IRF1-222 
qPCR further corroborated these results with E592R and I559F (Figure 4 E). 223 
We also measured STAT1 activation with longer IFNγ stimulation times to estimate rule 224 
out simply delayed signaling kinetics 27, and found no activation of STAT1 with E592R or 225 
F537A mutants even at long time-scales (Figure S2 D). 226 
Characterization of JAK2 GOF activation mechanisms by suppressor mutations 227 
JAK2 V617F hyperactivation relies on the interaction with cytokine receptors but the 228 
underlying mechanisms are still elusive 28-30. Disruption of FERM and receptor binding of 229 
JAKs to receptors is a potential mechanism of suppression 28, and it has been suggested 230 
that some JAK3 JH2 mutations (including a JH2 ATP-binding site mutation) could affect 231 
subcellular localization of JAK3 31. We assessed subcellular localization of our suppressing 232 
mutations by imaging JAK2-YFP fusion proteins, but found no effect for either mutation on 233 
subcellular localization, either with or without added EPOR-HA (Figure 5 A). In contrast, 234 
JAK2-YFP with Y119E, known to cause dissociation from receptors 29,32, showed 235 

















We speculated that mutation-induced JAK2-receptor dimerization is part of the activation 237 
mechanism of JAK2 GOF mutations. We thus analyzed whether suppressing mutations 238 
directly affect the propensity of JAK2 to dimerize on receptors. Using a FRET-based 239 
EPOR-CFP/YFP receptor dimerization assay in the JAK2-deficient γ2A fibroblast cell line 240 
(lacking endogenous EPOR expression) along with our JAK2-HA mutant constructs 241 
showed that E592R significantly reduces basal JAK2-EPOR dimerization (Figure 5 B). 242 
I559F, in contrast, showed a slight increase in dimerization, but this was within 243 
experimental noise and not significant. 244 
To directly assess whether decreased dimerization propensity also translates to decreased 245 
receptor-mediated JAK2 activation, we assessed basal activation of otherwise wild-type 246 
JAK2. EPOR-HA overexpression (known to induce ligand-independent activation 16) 247 
alongside expression of JAK2 mutants showed that all suppressing mutations, irrespective 248 
of their mode of action, suppress EPOR-induced JAK2 activation (Figure 5 C), suggesting 249 
that other mechanisms beyond lowering of dimerization propensity (as shown for E592R 250 
(Figure 5 B), and potentially also true for other αC mutations) are likely at play to explain 251 
the mode of action of suppressing JH2 ATP-binding site mutations. We thus measured 252 
whether mutating the JH2 ATP-binding site or αC directly affects the enzymatic activity of 253 
JH1. Indeed, kinase assays with recombinant JAK2 JH2-JH1 fragments in vitro showed 254 
unchanged Km, ATP values for both JH2 mutations I559F and E592R, but lowered kinase 255 
reaction catalysis rates (kcat) for I559F (Figure 5 D). 256 
Taken together, these data suggest that the mechanisms of suppression of JH2 ATP-257 
binding site and αC mutations are different. Inhibiting ATP binding to JH2 directly lowers 258 
catalytic activity of JH1, potentially through lowering the stability of the JH2 αC 16, and thus 259 

















(e.g., with E592R), on the other hand, inhibits the propensity of JAK2 to dimerize and 261 


















The molecular mechanisms of JAK activation by cytokine or mutation have long been 264 
elusive and here we have performed a systematic analysis of JAK2 activation mechanisms 265 
using structure-guided mutagenesis. Our results shed light on not only the mechanism of 266 
cytokine-independent JAK2 activation, but also identify a previously unknown interface on 267 
JH2 involved in JAK2-mediated receptor dimerization and needed especially for 268 
heteromeric JAK signaling. 269 
Our results enable grouping of activating JAK2 mutations based on their requirements for 270 
distinct structural elements and thus activation mechanisms. Both V617F and R683S were 271 
sensitive to mutations affecting the JH2 ATP binding site and αC, albeit their suppressing 272 
effects showed differences, i.e., αC mutations completely abrogated V617F but not 273 
R683S, while JH2 ATP-binding site mutations showed similar suppression of both. The 274 
effect of suppressing mutations were more pronounced at pJAK2 and pSTAT1 than on 275 
STAT5 reporter assays which may reflect technical differences (e.g., stability of luciferase), 276 
or be indicative of signal amplification in the JAK-STAT pathway. Previously, we have 277 
shown that a suppressing JH2 ATP-binding site mutation reverts the increased hematocrit 278 
in a mouse V617F MPN model 16. 279 
The resistance of K539L compared to V617F and R683S to suppressing mutations is 280 
interesting, since K539 and V617 reside near each other in the JH2 structure (Figure 1), 281 
and suggests a distinct activation mechanism for K539L. R683S likely activates through 282 
breaking the autoinhibitory interface resulting in increased conformational freedom and 283 
activation of JH1. This freed JH1 does, however, still rely on correct JH2-mediated 284 
positioning for ligand-independent activation, as well as JAK2-mediated receptor 285 
dimerization (see V511R and αC mutations, respectively in Figure 2). In contrast, K539L is 286 

















analysis is consistent with a more direct activation mechanism of K539L, potentially 288 
involving direct activation of JH1, e.g., through interaction with K857 on JH1 22. Consistent 289 
with previous reports, K539L is effectively inhibited only by F595A, which is known 290 
primarily for participating in stabilizing interactions in JH2 αC in the context of V617F 291 
hyperactivation 24,25, but which has been suggested to alter the stability of the JH2 αC also 292 
more broadly . 293 
For V617F, our results show complete inhibition by αC mutations including E592R, which 294 
our FRET-data indicate to interfere with JAK2-mediated receptor dimerization (Figure 5 B). 295 
We thus hypothesize that V617F activates JAK2 mostly by enhancing the propensity of 296 
JAK2 to dimerize on a receptor. This is in line with previous reports with recombinant JAK2 297 
and TYK2 JH2-JH1 fragments, which showed only modest activation of kinase activity with 298 
the JAK2 V617F or analogous TYK2 V678F mutation in an isolated in vitro setting, which 299 
does not include JAK-mediated receptor dimerization effects 9,33. Our mutagenesis data 300 
furthermore suggests, that the dimerization interface directly includes the JH2 αC, with 301 
E592 (and probably E596) involved. 302 
Our analysis of suppressing mutations in an otherwise wild-type background shows that, 303 
contrary to previous reports 16,22,24, suppressing mutations do affect JAK2 WT activity by 304 
lowering both basal (Figure 5 C), as well as ligand-dependent activation (Figure 4). 305 
Interestingly, quantitative comparison of potency of individual suppressing mutations to 306 
inhibit activation by V617F and cytokine reveals that these two correlate clearly (Figure 307 
S3). The correlating suppression of ligand-dependent and -independent JAK2 activation 308 
suggests that the same JH2 interface (αC and C-terminus of SH2-JH2 linker) is used in 309 
both settings. Furthermore, imaging data of JAK2-YFP shows unaltered subcellular 310 
distribution of JAK2 carrying suppressing mutations (Figure 5 A) ruling out direct 311 

















Our results also reveal that JH2 αC suppressing mutations most likely inhibit JAK2 313 
activation by suppressing JAK2 dimerization (Figure 5 B), while JH2 ATP-binding site 314 
mutations exert their suppressing effects by directly affecting tyrosine kinase activity of 315 
JAK2 JH1 (Figure 5 D), potentially through partial destabilization of JH2 αC 12,16. We thus 316 
conclude, that V617F and R683S most likely activate JAK2 by increasing its propensity for 317 
dimerization, and that this is counteracted by suppressing mutations in the JH2 αC 318 
(E592R, E596R, F595A) and SH2-JH2 linker (F537A). For the case of R683S, which lies 319 
directly in the JH2-JH1 autoinhibitory interface (Figure 1 and refs 9,12), we speculate that 320 
weakening of the autoinhibitory interaction releases JH2, which relieves autoinhibition on 321 
JH1, as well as exposing the dimerization interface on JH2. 322 
The molecular details of heteromeric JAK activation have remained largely unknown. Our 323 
analysis of cytokine-stimulation of JAK2 carrying suppressing mutations strikingly suggest 324 
that the same interface needed for activation by V617F or R683S by dimerization of 325 
(receptor-bound) JAK2, is crucial especially for heteromeric activation of JAK2. This 326 
finding refines earlier work that showed a critical role for JH2 in JAK activation 7,11. 327 
Previous studies have shown in several cytokine receptor systems that catalytic activity of 328 
both JAKs is not required for heteromeric JAK activation 20,34. For instance, in IFNγ 329 
signaling STAT1 does not require enzymatically functional JAK1 35, but does require the 330 
presence of JAK1 JH2 36. Pathway-specific JAK substructures have also been implicated 331 
in JAK2 JH1 for EPO signaling 37. Our results refine these findings by identifying the C-332 
terminus of the SH2-JH2 linker and JH2 αC as critical for heteromeric JAK activation. 333 
However, whether the JH2 interface identified here participates in JAK2-JAK2 or JAK2-334 
JAK1 dimers/multimers on IFNGR remains a topic for future research. 335 
Currently available JAK inhibitors show beneficial clinical responses, but there is a clear 336 

















question for this goal is to understand the differential mechanisms defining pathogenic and 338 
different cytokine-induced activation modes. Our results presented here provide insights 339 
into these questions and identify specific regions in JH2 that are differentially required for 340 
JAK2 activation in different contexts. These findings pave the way for the design of novel, 341 
potentially mutant and/or pathway-selective pharmacological compounds. 342 
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Figure Legends 488 
Figure 1: JAK2 domain structure. A: Structures of JAK2 FERM-SH2 (left, PDB: 4Z32) 489 
with model of EPOR JAK2-binding peptide shown in dark blue (modelled based on 490 
Interferon λ 1 receptor (IFNLR1) peptide bound to JAK1 FERM-SH2, PDB: 5L04), and 491 
JAK2 JH2-JH1 inhibitory interaction 12. Right: JAK2 JH2-JH1 top view. B: Domain structure 492 
of JAK2. See also Table 1. 493 
Figure 2: Suppressing JAK2 mutations reveal distinct activation mechanisms for 494 
different JAK2 gain-of-function (GOF) mutations. A: Representative immunoblots of 495 
whole-cell lysates from JAK2-deficient γ2A cells transiently transfected with full-length 496 
JAK2-HA mutants as indicated. pJAK2, JAK2 activation loop phosphorylation 497 
JAK2(Y1007/1008); pSTAT1, STAT1(Y701) phosphorylation. GGAA, G552A+G554A. 498 
EEAA, E896A+E900A. Experiment was repeated twice with similar results. B and C: 499 
Quantification of immunoblots shown in A. a.u., arbitrary units. D: STAT5 reporter assay in 500 
the presence of transfected EPOR-HA. Averages and standard deviations from triplicate 501 
wells are shown as fold induction relative to unstimulated JAK2 WT. RLU, relative 502 
luminescence units. All reporter experiments were repeated twice with similar results. 503 
 504 
Figure 3: Suppression of V617F activation by secondary mutations restores 505 
cytokine sensitivity. A: STAT5 reporter assay in the presence of transfected EPOR-HA. 506 
B: IFNγ/STAT1 reporter. A and B as described for Figure 2. C: quantitative PCR (qPCR) of 507 
IFNγ-induced interferon regulatory factor 1 (IRF1). Averages and standard deviations from 508 
two biological replicates each done in technical triplicates in qPCR are shown. Mutations 509 
are color-coded by type as in Figure 2. 510 
Figure 4: Analysis of suppressing mutations in JAK2 WT background. A and B: 511 

















in the presence of transfected EPOR-HA. D: IFNγ/STAT1 reporter assay. C and D as 513 
described for Figure 2. E: qPCR of IRF1 expression as described for Figure 3. Wild-type 514 
sample (WT) same as in Figure 3 C. Mutations are color-coded by type as in Figure 2. 515 
Experiments were repeated twice with similar results. 516 
Figure 5: Suppressing mutations localize correctly to the membrane, but  517 
differentially affect dimerization of JAK2-EPOR and kinase activity of recombinant 518 
JAK2 JH2-JH1. A: Representative confocal microscopy micrographs of fixed γ2A cells 519 
expressing the indicated JAK2-YFP mutations. B: Analysis of basal JAK2-EPOR 520 
dimerization. Normalized apparent FRET efficiency calculated from manually segmented 521 
cell membranes as detailed in Materials and Methods. Number of individual cells analyzed 522 
for each condition is indicated. Significance assessed by Student’s t test (unpaired). n.s. = 523 
not significant; *p < 0.05. C: Immunoblot analysis of whole-cell lysate from γ2A cells 524 
transiently transfected with the JAK2-HA constructs and EPOR-HA as shown. D: Kinase 525 
assay with purified recombinant JAK2 JH2-JH1. Shown are averages and standard 526 

















Tables and Table Legends 528 
Table 1: Used JAK2 mutations and their presumed mode of action or experimental 529 
rationale. See also Figure 1. 530 
Mutation Substructure Rationale / mode of action Reference 
Y119E FERM F1 
Mimics Y119 phosphorylation. Previously reported 
to induce dissociation of JAK2 from receptor. 
29,32 
V511R SH2 
Designed to disrupt SH2-JH2 linker from FERM-
SH2. - 
F537A SH2-JH2 link 
F537 proposed to stack with F595 in JAK2 JH2 
WT. Known to inhibit V617F. 
26 





Designed to remove flexible glycines usually 
needed for ATP binding. 
16 
I559F JH2 β2 
Designed to sterically inhibit ATP binding. Verified 
to inhibit ATP binding 16. 
16 
K581A JH2 β3 Removes conserved β3 lysine. 16,39 
E592R JH2 αC Outer face of JH2 αC 12 
F595A JH2 αC 
Inner face of JH2 αC. Known to inhibit V617F and 
others by potentially destabilizing JH2 and making 
space for F617 (ref 12). 
12,23-25 
E596R JH2 αC Outer face of JH2 αC. Known to inhibit V617F and 
others. Mechanism unknown. 
22 
V617F JH2 β4-β5 
loop 
Activating, potentially by disturbing SH2-JH2 linker. 
Causes MPNs. 
40-43 
K677E JH2 β6-β7 
loop 
Designed to inhibit ATP binding electrostatically. 





Activating, probably by breaking R683-D873 
interaction over inhibitory JH2-JH1 interface. 
Causes ALL. 
44,45 
T875N JH1 β2-β3 
loop 
Activating, mechanism probably similar to R683S. 
Causes AMKL. 
46 
L884P JH1 β3-αC 
loop 
Activating by unknown mechanism. Homologous to 




JH1 αC Outer face of JH1 αC. - 
D976N JH1 β6-β7 
loop 
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Supplementary 
Materials and Methods 
Plasmid constructs and mutagenesis. Full-length human JAK2 and erythropoietin 
receptor (EPOR) were cloned into pCIneo expression vector using SalI-NotI restriction 
sites. Full-length human STAT5A was in pXM vector. JAK2 and STAT5A were C-terminally 
hemagglutinin (HA)-tagged. EPOR was HA-tagged N-terminally after the signal peptide 
(between residues 30 and 31). Site-directed mutagenesis was performed using 
QuikChange (Agilent) according to manufacturer’s instructions, and verified by Sanger 
sequencing. For luciferase reporter assays, Firefly luciferase reporter constructs for 
STAT5 (Spi-Luc 1) or STAT1 (IRF-GAS 2) was used together with a constitutively 
expressing Renilla luciferase plasmid. For analysis of subcellular localization of JAK2 
mutants, JAK2-YFP fusion constructs were made by cloning JAK2 without stop codon to 
pEGFP vector using SalI-XmaI restriction sites. The YFP variant (mCitrine – gift from 
Robert Campbell, Michael Davidson, Oliver Griesbeck, Roger Tsien; Addgene plasmid 
#54594) was cloned to XmaI-NotI restriction sites resulting in the JAK2-YFP fusion 
construct. A short flexible linker (amino acids RSIAT) was also inserted between JAK2 and 
YFP during cloning.  EPOR FRET reporter constructs were created by fusing CFP or YFP 
to the N-terminus of EPOR truncated after residue 340 by overlap extension PCR. The 
fused EPOR-YFP and EPOR-CFP fragments were cloned to the bidirectional pBOF-vector 
3 to ensure equal expression of the EPOR FRET pair. Cotransfection with pTetOn vector 
and doxycycline (0.1 µg/ml) was used during transfection to induce expression of FRET 
reporter constructs.   
Mammalian cell culture. JAK2-deficient γ2A human fibrosarcoma cells 4 were cultured 
using standard culturing conditions in DMEM (Lonza) supplemented with 10% fetal bovine 
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For transfection, cells were seeded on 6-, 12-, or 24-well tissue culture plates and 
transfected using FuGENE HD (Promega) according to manufacturer’s instructions. Cells 
were transfected for 24–48 h and, where needed, cytokine stimulated in starvation medium 
without FBS for 30 min (for immunoblotting) or 5 h (for reporter assays) unless otherwise 
specified, with human recombinant EPO (NeoRecormon, Roche), or human recombinant 
IFNγ (Peprotech). 
Immunoblotting. After transfection/stimulation, cells were washed with ice-cold PBS, and 
lysates collected in cold lysis buffer (50 mM Tris-Cl pH 7.5, 10% glycerol, 150 mM NaCl, 1 
mM EDTA, 1% Triton X-100, 50 mM NaF, 2 mM vanadate, 8.3 µg/ml aprotinin, 4.2 µg/ml 
pepstatin, and 1 mM phenylmethanesulfonyl fluoride). Lysates were centrifuged and used 
directly for SDS-PAGE/immunoblotting or stored at -20 °C. Immunoblots were blocked with 
bovine serum albumin (BSA) and double-stained with the following diluted primary 
antibodies: HA Tag (1:2000, Aviva Systems Biology OAEA00009), phospho-JAK2 (1:1000, 
Tyr1007/1008, Millipore 07-606), phospho-STAT5 (1:1000, Tyr694, Cell Signaling 9351), 
phospho-STAT1 (1:1000, Tyr701 (D4A7), Cell Signaling 7649), STAT1 (1:1000, BD 
Biosciences 610116), or actin (1:1000, Millipore MAB1501R). Signals were detected using 
a mixture of goat-anti-rabbit (DyLight 680) and goant-anti-mouse (DyLight 800, Thermo 
Scientific) secondary antibodies (both at 1:5000 dilution) and read using an Odyssey CLx 
(LI-COR). Quantification of immunoblot signals was done using Image Studio software (LI-
COR) by manually assigning bands to be quantified. For STAT1, only the larger isoform 
(STAT1α) was assessed. Control experiments were carried out to ensure that signals were 
within the quasi-linear range of the detection method (See Figure S1). 
Luciferase reporter assays. For reporter assays, cells were seeded on 6 or 12-well 
plates, transfected overnight, transferred onto 96-well plates, let attach overnight, and 
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reporter assay kit (Promega) according to manufacturer’s instructions. Luminescence was 
read on an EnVision multiplate reader (Perkin Elmer), and results calculated as Firefly 
luciferase luminescence divided by Renilla luciferase luminescence and normalized to 
readings from wells of unstimulated cells transfected with JAK2 WT. 
RNA isolation and qPCR. For quantitative PCR (qPCR) analysis, γ2A cells were 
transfected as described above for 28 h, starved for 16 h, stimulated for 2 h with 10 U/ml 
EPO or 10 ng/ml IFNγ, and then RNA extracted using TRI Reagent (Molecular Research 
Center) according to manufacturer’s instructions. Total RNA (0.2 µg) was reverse 
transcribed using M-MuLV reverse transcriptase (Thermo Scientific) according to 
manufacturer’s instructions. qPCR reactions with the cDNAs were made using HOT 
FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne) and primers specific for IRF1 which 
is an IFNγ responsive gene (Primers- 5’-GCATGAGACCCTGGCTAGAG-3’ and 5’-
CTCCGGAACAAACAGGCATC-3’). The qPCR reaction was performed using Bio-Rad 
CFX-384 Real-Time PCR detection system and the gene expression was quantified using 
comparative C(T) method by normalizing to the expression of TATA-box binding protein 
(TBP). 
Recombinant protein production, purification, and in vitro kinase assay. 
Recombinant human JAK2 JH2-JH1 (513–1132-6xHis) WT, I559F, and E592R proteins 
were expressed in High Five insect cells (Thermo Fisher Scientific) using the Bac-to-Bac 
baculovirus expression system (Invitrogen) according to manufacturer’s instructions. After 
protein expression (10% P3 virus, 48 h, 27 oC), the cells were collected by centrifugation, 
resuspended in lysis buffer containing 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10% 
glycerol, 20 mM imidazole supplemented with phosphatase and protease inhibitors (100 
mM sodium orthovanadate, 100 mM PMSF, 10 µg/ml pepstatin A), and lysed by applying 
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proteins were purified using Ni-NTA agarose (Qiagen) and size-exclusion chromatography 
in HiLoad 16/600 Superdex 75 pg column (GE Healthcare) equilibrated in 20 mM Tris-HCl 
pH 8.0, 500 mM NaCl, 10% glycerol, 0.5 mM TCEP. Protein concentrations were 
determined by Bradford assay (Bio-Rad) according to manufacturer’s instructions. 
Enzymatic activity of JAK2 JH2-JH1 WT and mutant proteins was determined by time-
resolved (TR-)FRET-based Lance Ultra kinase assay (PerkinElmer) under conditions 
recommended by the manufacturer. Kinase reactions: 100 nM tyrosine kinase substrate 
ULight™-poly GT, recombinant JAK2 JH2-JH1 WT (60 pM), I559F (150 pM) or E592R (60 
pM), 2 nM Eu-labeled anti-phospho antibody, and ATP concentration range of 0–1000 µM, 
were set up in kinase buffer (50 mM Tris-HCl pH 8.0, 10 mM MgCl2, 1 mM EGTA, 0.05% 
BSA, 0.01% Brij-35, and 0.5 mM TCEP) on 384-plates (AlphaPlate-384 SW, PerkinElmer). 
Substrate phosphorylation was detected by measuring TR-FRET (ex. 320 nm, em. 665 
nm) in 5 min intervals for 2 h at room temperature using EnVision Multilabel plate reader 
(PerkinElmer). Activity parameters kcat and Km were calculated by fitting reaction velocity 
vs. ATP concentration in GraphPad Prism (GraphPad Software). Kinase reactions were 
performed in triplicate and results shown are representative data from 2–3 individual 
experiments. 
Microscopy and FRET assay to quantify JAK2 dimerization. For microscopy, cells 
were seeded on 35 mm glass bottom dish (MatTek), transfected overnight as described 
above and starved for 8 h. Cells were fixed with 4% paraformaldehyde and 0.1% 
glutaraldehyde for 15 minutes in room temperature, washed and kept in PBS at 4 °C 
before imaging. The cells were imaged using a Zeiss LSM 780 laser scanning confocal 
microscope using a Plan Apochromat 63x/1.4 oil immersion objective and images were 
acquired with 458 nm and 514 nm excitation laser for CFP and YFP, respectively. 
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32-channel QUASAR GaAsP PMT array detector. FRET was monitored by acceptor 
photobleaching 5 using 514 nm laser and the images were processed with ImageJ. Cell 
images were sorted based on the expression levels by measuring acceptor fluorescence 
before photobleaching (independent of FRET) and only cells with approximately equal 
levels of expression for different constructs were used for the analysis. The cell membrane 
region was manually segmented for each cell, and FRET efficiency was calculated only 














Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations 
Hammarén et al. 
Supplementary References 
(1) Sliva D, Wood TJ, Schindler C, Lobie PE, Norstedt G. Growth hormone specifically 
regulates serine protease inhibitor gene transcription via gamma-activated sequence-like 
DNA elements. J Biol Chem 1994 Oct 21;269(42):26208-26214. 
(2) Pine R, Canova A, Schindler C. Tyrosine phosphorylated p91 binds to a single element 
in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is 
likely to autoregulate the p91 gene. EMBO J 1994 Jan 1;13(1):158-167. 
(3) Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, et al. Jak1 Has a 
Dominant Role over Jak3 in Signal Transduction through [gamma] c-Containing Cytokine 
Receptors. Chem Biol 2011;18(3):314-323. 
(4) Kohlhuber F, Rogers NC, Watling D, Feng J, Guschin D, Briscoe J, et al. A JAK1/JAK2 
chimera can sustain alpha and gamma interferon responses. Mol Cell Biol 1997 
Feb;17(2):695-706. 
(5) Bastiaens P, Majoul IV, Verveer PJ, Söling H, Jovin TM. Imaging the intracellular 
trafficking and state of the AB5 quaternary structure of cholera toxin. EMBO J 
1996;15(16):4246-4253. 













Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations 
Hammarén et al. 
Supplementary Figure Legends 
Figure S1: Validation of immunoblotting quantification method. A: Control 
immunoblot from whole-cell lysate of γ2A cells transiently transfected with JAK2-HA WT or 
JAK2-HA V617F as indicated. Lysates were run at different dilutions in lysis buffer to 
gauge linearity of immunoblotting signal. For detection, immunoblot is cut into three pieces 
(indicated with dashed lines) and the pieces double stained with Anti-pJAK2 + Anti-HA or 
Anti-pSTAT1 + STAT1, or single-stained with Anti-Actin. B: Example of quantification 
procedure using ImageStudio software (LICOR Biosciences). Shown is an example area 
from the immunoblot shown in (A) and indicated by a white dotted line. Bold blue boxes 
are the manually assigned areas of interest, each encompassing a single band (note, e.g., 
that for STAT1, only STAT1α is quantified). The light blue boxes on top and below each 
band are used to calculate the local background from the lane. From the background, the 
median signal intensity is used as a background value, which is deducted from the total 
signal from the area of interest. C: pJAK2 and total JAK2-HA quantifications showing the 
approximate linearity of the signal over the measured intensity range. Last panel shows 
the ratio of pJAK2 and JAK2-HA signal intensities, which is used as a measure of 
phosphorylation status (“Normalized pJAK2”). The point of deviation from linearity on the 
normalized pJAK2 panel shows the limits of pJAK2+JAK2-HA quantifiability (down to 
pJAK2 signal intensities of ~50), thus limiting the direct comparison of pJAK2 values to 
samples with relatively strong pJAK2 signals. D: pSTAT1 and total STAT1 quantifications 
as delineated above for (C). Note the exceptional linearity of STAT1 signals (and the 
ensuing stability of the normalized pSTAT1 value in the last panel), thus rendering 
pSTAT1 better suited for comparison of samples over a wide range of pSTAT1 signal 
intensities. E: Quantification of Actin signals showing poor linearity over the tested range. 
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Figure S2: Characterization of effects of suppressing mutation on cytokine 
signaling in JAK2 WT background. Related to Figure 4. A and B: Immunoblots related 
to Figure 4 A and B, respectively. Immunoblots of whole-cell lysates from γ2A cells 
transiently transfected with full-length JAK2-HA (and mutants thereof), STAT5-HA, and 
EPOR-HA (A) or full-length JAK2-HA mutants only (B), and stimulated with the indicated 
amount of cytokine for 30 min. Quantification of immunoblots was done as shown in Figure 
S1.  C: Related to Figure 4 E, qPCR of IRF1 from RNA extracted from γ2A cells transiently 
transfected with JAK2-HA mutants and stimulated with EPO for 2 h showing the specificity 
of IRF1 induction. D: Immunoblots of whole-cell lysates from γ2A cells transiently 
transfected with full-length JAK2-HA mutants and stimulated with 1 µg/ml IFNγ for the 
indicated times before lysis. JAK2-HA E592R and F537A show no induction of pSTAT1 
even at longer stimulation times. 
 Figure S3: JAK2 activation by V617F relies on the same interfaces to activate as 
JAK2 activation by cytokine. Suppression calculated as STAT5 or STAT1 reporter 
activity relative to basal activity of JAK2 V617F (y-axes) and stimulated wild-type JAK2 (10 
U/ml EPO or 5 ng/ml IFNγ; x-axes). Data for figure is from the same experiments as for 
Figures 2 and 3. 
